PIK3CA and neoplasm: Previously we showed that a subset of cervical cancer patients with PIK3CA exon 9 or 20 mutations had significantly worse clinical outcomes after radiation therapy (RT) and cisplatin chemotherapy than patients whose tumours expressed wild-type PIK3CA [27].